Cue Price To Sales Ratio vs Capex To Operating Cash Flow Analysis

CUE Stock  USD 1.01  0.01  0.98%   
Cue Biopharma financial indicator trend analysis is way more than just evaluating Cue Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cue Biopharma is a good investment. Please check the relationship between Cue Biopharma Price To Sales Ratio and its Capex To Operating Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.

Price To Sales Ratio vs Capex To Operating Cash Flow

Price To Sales Ratio vs Capex To Operating Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cue Biopharma Price To Sales Ratio account and Capex To Operating Cash Flow. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Cue Biopharma's Price To Sales Ratio and Capex To Operating Cash Flow is -0.3. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Capex To Operating Cash Flow in the same time period over historical financial statements of Cue Biopharma, assuming nothing else is changed. The correlation between historical values of Cue Biopharma's Price To Sales Ratio and Capex To Operating Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Cue Biopharma are associated (or correlated) with its Capex To Operating Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Operating Cash Flow has no effect on the direction of Price To Sales Ratio i.e., Cue Biopharma's Price To Sales Ratio and Capex To Operating Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.3
Relationship DirectionNegative 
Relationship StrengthInsignificant

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Cue Biopharma stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cue Biopharma sales, a figure that is much harder to manipulate than other Cue Biopharma multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Capex To Operating Cash Flow

Most indicators from Cue Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cue Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.The current year's Issuance Of Capital Stock is expected to grow to about 24 M, whereas Selling General Administrative is forecasted to decline to about 11.7 M.
 2021 2022 2023 2024 (projected)
Interest Income45.9K928.2K2.7M2.8M
Net Interest Income45.9K214.4K1.4M1.5M

Cue Biopharma fundamental ratios Correlations

0.280.910.990.660.970.9-0.91-0.780.830.960.910.870.860.990.860.610.540.760.910.890.910.820.851.00.88
0.280.360.190.370.340.3-0.02-0.660.520.170.340.420.460.240.560.550.280.610.160.50.490.380.390.260.58
0.910.360.860.540.950.9-0.8-0.880.90.880.920.930.960.880.940.80.420.760.90.950.960.750.870.90.94
0.990.190.860.680.940.85-0.95-0.70.760.970.850.80.770.980.780.510.490.670.870.810.830.820.780.990.8
0.660.370.540.680.660.38-0.66-0.380.550.630.420.510.50.660.510.160.50.410.490.470.520.930.320.690.52
0.970.340.950.940.660.86-0.91-0.820.890.970.870.840.870.960.920.730.410.720.860.920.920.840.830.970.92
0.90.30.90.850.380.86-0.72-0.850.820.821.00.930.910.850.870.730.480.830.890.930.930.60.980.860.88
-0.91-0.02-0.8-0.95-0.66-0.91-0.720.57-0.68-0.98-0.72-0.64-0.64-0.92-0.67-0.44-0.25-0.43-0.78-0.71-0.7-0.79-0.65-0.93-0.69
-0.78-0.66-0.88-0.7-0.38-0.82-0.850.57-0.9-0.72-0.86-0.83-0.87-0.75-0.92-0.9-0.32-0.83-0.77-0.94-0.91-0.59-0.88-0.75-0.94
0.830.520.90.760.550.890.82-0.68-0.90.780.830.810.870.830.950.860.410.820.840.950.920.790.860.810.96
0.960.170.880.970.630.970.82-0.98-0.720.780.820.740.750.970.80.590.310.590.830.830.810.790.770.970.81
0.910.340.920.850.420.871.0-0.72-0.860.830.820.960.950.850.880.740.530.850.90.940.950.640.970.870.9
0.870.420.930.80.510.840.93-0.64-0.830.810.740.960.990.790.880.690.640.860.880.90.960.680.890.840.89
0.860.460.960.770.50.870.91-0.64-0.870.870.750.950.990.790.930.780.570.860.870.940.980.70.90.820.93
0.990.240.880.980.660.960.85-0.92-0.750.830.970.850.790.790.830.60.510.720.90.860.870.830.810.990.85
0.860.560.940.780.510.920.87-0.67-0.920.950.80.880.880.930.830.90.470.880.810.990.970.740.90.841.0
0.610.550.80.510.160.730.73-0.44-0.90.860.590.740.690.780.60.90.170.740.630.90.830.450.810.580.89
0.540.280.420.490.50.410.48-0.25-0.320.410.310.530.640.570.510.470.170.750.540.450.580.520.440.530.47
0.760.610.760.670.410.720.83-0.43-0.830.820.590.850.860.860.720.880.740.750.750.880.910.60.860.720.89
0.910.160.90.870.490.860.89-0.78-0.770.840.830.90.880.870.90.810.630.540.750.860.890.710.840.890.82
0.890.50.950.810.470.920.93-0.71-0.940.950.830.940.90.940.860.990.90.450.880.860.980.710.950.860.99
0.910.490.960.830.520.920.93-0.7-0.910.920.810.950.960.980.870.970.830.580.910.890.980.730.920.880.98
0.820.380.750.820.930.840.6-0.79-0.590.790.790.640.680.70.830.740.450.520.60.710.710.730.570.840.75
0.850.390.870.780.320.830.98-0.65-0.880.860.770.970.890.90.810.90.810.440.860.840.950.920.570.810.91
1.00.260.90.990.690.970.86-0.93-0.750.810.970.870.840.820.990.840.580.530.720.890.860.880.840.810.85
0.880.580.940.80.520.920.88-0.69-0.940.960.810.90.890.930.851.00.890.470.890.820.990.980.750.910.85
Click cells to compare fundamentals

Cue Biopharma Account Relationship Matchups

Cue Biopharma fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets71.6M99.5M83.4M91.3M61.5M66.4M
Other Current Liab2.2M(2.0M)333.6K3.6M4.1M4.3M
Total Current Liabilities11.7M16.3M12.8M11.5M17.1M10.1M
Total Stockholder Equity54.6M78.9M65.5M65.7M37.1M51.3M
Net Tangible Assets54.6M78.9M65.5M65.7M75.5M52.6M
Property Plant And Equipment Net7.2M8.9M11.9M10.7M7.1M6.4M
Net Debt(38.5M)(67.7M)(54.3M)(32.3M)(33.8M)(35.5M)
Retained Earnings(108.5M)(153.3M)(197.4M)(250.5M)(301.2M)(286.1M)
Accounts Payable882.7K2.1M2.6M2.7M3.5M1.9M
Cash44.3M74.9M64.4M51.6M48.5M47.6M
Non Current Assets Total10.6M12.0M14.9M14.1M10.1M8.6M
Non Currrent Assets Other3.4M3.0M2.9M3.2M2.8M2.1M
Other Assets3.4M3.1M3.0M3.4M3.9M2.1M
Cash And Short Term Investments44.3M84.9M64.4M76.3M48.5M54.1M
Common Stock Total Equity26.6K30.4K32.2K43.0K49.5K26.3K
Common Stock Shares Outstanding22.0M28.7M31.3M35.6M45.8M30.0M
Short Term Investments50.1K18.4M15.1M10.0M0.024.7M
Liabilities And Stockholders Equity71.6M99.5M83.4M91.3M61.5M66.4M
Non Current Liabilities Total5.4M4.3M5.1M14.1M7.4M5.1M
Other Current Assets860.1K2.5M1.8M1.7M1.2M1.2M
Other Stockholder Equity163.1M232.2M262.9M316.2M338.2M189.1M
Total Liab17.0M20.6M17.9M25.6M24.4M15.1M
Property Plant And Equipment Gross7.2M8.9M15.4M14.9M10.7M7.7M
Total Current Assets61.0M87.5M68.5M77.2M51.5M57.8M
Accumulated Other Comprehensive Income(10.3K)7.1K0.0(95.9K)(110.3K)(115.8K)
Common Stock26.6K30.4K32.2K43.0K47K29.1K
Property Plant Equipment7.2M2.1M2.1M1.5M1.7M2.6M
Non Current Liabilities Other5.4M4.3M5.1M6.0M6.9M4.8M
Current Deferred Revenue4.1M6.7M645.3K2.1M2.4M3.0M
Net Invested Capital54.6M78.9M65.5M75.7M45.3M65.7M
Net Working Capital49.4M71.2M55.7M65.6M34.4M42.3M
Retained Earnings Total Equity(108.5M)(153.3M)(197.4M)(250.5M)(225.4M)(236.7M)
Capital Surpluse163.1M232.2M262.9M316.2M363.6M237.6M
Capital Stock26.6K30.4K32.2K43.0K47K36.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.91)
Revenue Per Share
0.172
Quarterly Revenue Growth
0.923
Return On Assets
(0.52)
Return On Equity
(1.39)
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.